Entries by melindaroberts

Should All Potentially Lethal Tumors Be Sequenced?

Lisandra E. West, PhD, Senior Scientific Knowledge Engineer, CollabRx. Q: Is there enough benefit to justify sequencing all patients’ tumors? – Perspective from a scientific knowledge engineer. A: As a scientist […]

Can Precision Oncology Develop Despite Pharmaphobia?

Thomas P. Stossel, MD, American Cancer Society Professor of Medicine, Harvard Medical School; Senior Physician, Hematology Division, Brigham & Women’s Hospital, Boston, MA; Visiting Scholar, American Enterprise Institute; Secretary, Options […]

How do Phase 1 Clinical Trials for Cancer Drugs Work?

Razelle Kurzrock, MD, Chief, Division of Hematology and Oncology,UCSD School of Medicine; Senior Deputy Director, Clinical Science; Director, Center for Personalized Cancer Therapy; Director, Clinical Trials Office, UCSD Moores Cancer […]

NextGenU.org and the Prevention of Cancer

Erica Frank, MD, MPH, Professor and Canada Research Chair, University of British Columbia; Founder and President, NextGenU.org; Founding Member, CollabRx Editorial Advisory Board Q: What is Next Gen U and […]

Targeted Therapy and/or Immunotherapy for Cancer

Paul R. Billings MD, PhD, Internist, Clinical Geneticist, and Immunologist: Founder and Executive Chairman, PlumCare LLC; Chairman, Biological Dynamics Inc; Co-Founder and Chief Medical Officer, Omicia; Principal, Bethesda Group LLC; […]

Managing Metastatic Colorectal Cancer

Bassel El-Rayes, MD, Professor and Vice Chair for Clinical Research, Department of Hematology and Medical Oncology, Associate Director for Clinical Research, and Director of the Gastrointestinal Oncology Program Winship Cancer […]

Compassionate Use of Investigational Drugs

Arthur L Caplan, PhD Director, Division of Medical Ethics, NYU Langone Medical Center. Amrit Ray MD, MBA, Chief Medical Officer, Janssen Pharmaceutical Companies of Johnson & Johnson. Q: What is the ethical […]